166 related articles for article (PubMed ID: 18644518)
21. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
23. [Medical treatment of early breast cancer: chemotherapy].
Ejlertsen B; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab and cardiotoxicity: weighing the risks.
Wong SF
Am J Health Syst Pharm; 2006 Mar; 63(6):525. PubMed ID: 16522888
[No Abstract] [Full Text] [Related]
25. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity of trastuzumab in clinical practice.
McArthur HL; Chia S
N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
[No Abstract] [Full Text] [Related]
27. Trastuzumab-associated cardiotoxicity.
Keefe DL
Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab-induced cardiomyopathy.
Guglin M; Cutro R; Mishkin JD
J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
[TBL] [Abstract][Full Text] [Related]
29. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer.
Tang SC
Cancer Invest; 2009 Feb; 27(2):206-14. PubMed ID: 19235594
[TBL] [Abstract][Full Text] [Related]
30. From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
Eisenhauer EA
N Engl J Med; 2001 Mar; 344(11):841-2. PubMed ID: 11248162
[No Abstract] [Full Text] [Related]
31. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
Pritchard KI
Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
[No Abstract] [Full Text] [Related]
32. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab and breast cancer.
Palmieri C; Powles T; Vigushin D
N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
[No Abstract] [Full Text] [Related]
34. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
Suter TM; Cook-Bruns N; Barton C
Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab-induced cardiotoxicity.
Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
[TBL] [Abstract][Full Text] [Related]
36. Cardiology patient page. Breast cancer chemotherapy and your heart.
Unitt C; Montazeri K; Tolaney S; Moslehi J
Circulation; 2014 Jun; 129(25):e680-2. PubMed ID: 24958758
[No Abstract] [Full Text] [Related]
37. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
38. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.
Sukel MP; Breekveldt-Postma NS; Erkens JA; van der Linden PD; Beiderbeck AB; Coebergh JW; Herings RM
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):125-34. PubMed ID: 18058835
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
40. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J
Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
